Invitae Corporation (NVTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVTA POWR Grades
- NVTA scores best on the Growth dimension, with a Growth rank ahead of 73.54% of US stocks.
- The strongest trend for NVTA is in Stability, which has been heading down over the past 178 days.
- NVTA's current lowest rank is in the Sentiment metric (where it is better than 5.78% of US stocks).
NVTA Stock Summary
- Of note is the ratio of INVITAE CORP's sales and general administrative expense to its total operating expenses; just 5.22% of US stocks have a lower such ratio.
- In terms of twelve month growth in earnings before interest and taxes, INVITAE CORP is reporting a growth rate of 666.21%; that's higher than 97.5% of US stocks.
- The volatility of INVITAE CORP's share price is greater than that of 97.05% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to NVTA, based on their financial statements, market capitalization, and price volatility, are SSRM, MUR, AEM, MSTR, and IAG.
- Visit NVTA's SEC page to see the company's official filings. To visit the company's web site, go to www.invitae.com.
NVTA Valuation Summary
- NVTA's price/sales ratio is 1.9; this is 65.45% lower than that of the median Healthcare stock.
- Over the past 92 months, NVTA's EV/EBIT ratio has gone up 18.
Below are key valuation metrics over time for NVTA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NVTA | 2022-09-09 | 1.9 | 2.4 | -0.3 | -0.8 |
| NVTA | 2022-09-08 | 1.5 | 2.0 | -0.2 | -0.7 |
| NVTA | 2022-09-07 | 1.5 | 1.9 | -0.2 | -0.7 |
| NVTA | 2022-09-06 | 1.3 | 1.7 | -0.2 | -0.7 |
| NVTA | 2022-09-02 | 1.3 | 1.7 | -0.2 | -0.7 |
| NVTA | 2022-09-01 | 1.4 | 1.8 | -0.2 | -0.7 |
NVTA Growth Metrics
- The 2 year cash and equivalents growth rate now stands at 247.55%.
- Its 3 year net cashflow from operations growth rate is now at -604.62%.
- Its 3 year price growth rate is now at -76.66%.
The table below shows NVTA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 500.829 | -623.202 | -3,108.62 |
| 2022-03-31 | 480.519 | -617.838 | -451.373 |
| 2021-12-31 | 460.449 | -559.815 | -379.006 |
| 2021-09-30 | 434.759 | -497.479 | -408.22 |
| 2021-06-30 | 389.092 | -394.593 | -312.946 |
| 2021-03-31 | 318.971 | -325.662 | -613.135 |
NVTA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVTA has a Quality Grade of D, ranking ahead of 13.88% of graded US stocks.
- NVTA's asset turnover comes in at 0.118 -- ranking 73rd of 81 Healthcare stocks.
- BKD, VCYT, and HCSG are the stocks whose asset turnover ratios are most correlated with NVTA.
The table below shows NVTA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.118 | 0.281 | -0.331 |
| 2021-03-31 | 0.139 | 0.268 | -0.887 |
| 2020-12-31 | 0.183 | 0.291 | -1.070 |
| 2020-09-30 | 0.284 | 0.321 | -0.721 |
| 2020-06-30 | 0.280 | 0.347 | -0.790 |
| 2020-03-31 | 0.336 | 0.429 | -0.705 |
NVTA Stock Price Chart Interactive Chart >
NVTA Price/Volume Stats
| Current price | $2.44 | 52-week high | $32.22 |
| Prev. close | $2.56 | 52-week low | $1.83 |
| Day low | $2.37 | Volume | 6,403,900 |
| Day high | $2.53 | Avg. volume | 11,393,465 |
| 50-day MA | $3.12 | Dividend yield | N/A |
| 200-day MA | $6.78 | Market Cap | 574.05M |
Invitae Corporation (NVTA) Company Bio
Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.
Latest NVTA News From Around the Web
Below are the latest news stories about INVITAE CORP that investors may wish to consider to help them evaluate NVTA as an investment opportunity.
Why Invitae Stock Is Jumping TodayShares of Invitae (NYSE: NVTA) were jumping 6.7% higher as of 10:53 a.m. ET on Wednesday after rising as much as 12.9% earlier in the morning. On Tuesday, though, Invitae and Praxis Precision Medicines stated in a press release that Invitae's Citizen platform's clinical insights were used in Praxis' Investigational New Drug (IND) application for experimental drug PRAX-222 in treating epilepsy. Invitae's shares fell 5% yesterday. |
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND FilingFirst use of Ciitizen platform as source of real-world data in regulatory filingSAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developm |
Leading Clinical Experts Across the U.S. Unite to Support Universal Genetic Testing for all Patients with CancerInvitae (NYSE: NVTA), a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology, underscoring the importance of universal germline testing for all patients with cancer (solid tumors). The paper reports a meta-analysis of multiple clinical publications supporting universal testing, independent of age, stage, family history or type of cancer. It reports that for cancer types such as pancreatic and ovarian wher |
Why Shares of Invitae Dropped 13% on TuesdayShares of Invitae (NYSE: NVTA), a maker of medical genetic tests, fell 14% on Tuesday. Invitae's shares have been highly volatile and, earlier this month, shot up 277% the day it released second-quarter earnings. The drop comes a day after the company announced a collaboration with international research program Simons Searchlight. |
Invitae and Simons Searchlight Partner to Accelerate Research through Data SharingInvitae (NYSE: NVTA), a leading medical genetics company, today announced a collaboration with Simons Searchlight, an international research program with a goal of accelerating research and improving lives for people with rare genetic neurodevelopmental disorders. This partnership will connect two sets of data – the longitudinal clinical data extracted from medical records through Invitae's Ciitizen, a patient-consented, digital natural history data platform and patient reported outcomes and bio |
NVTA Price Returns
| 1-mo | -23.51% |
| 3-mo | -15.57% |
| 6-mo | -72.40% |
| 1-year | -91.88% |
| 3-year | -87.32% |
| 5-year | -72.71% |
| YTD | -84.02% |
| 2021 | -63.48% |
| 2020 | 159.21% |
| 2019 | 45.84% |
| 2018 | 21.81% |
| 2017 | 14.36% |
Continue Researching NVTA
Want to do more research on Invitae Corp's stock and its price? Try the links below:Invitae Corp (NVTA) Stock Price | Nasdaq
Invitae Corp (NVTA) Stock Quote, History and News - Yahoo Finance
Invitae Corp (NVTA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...